Share on StockTwits

Lannett Company (NYSE:LCI) Director Paul Taveira unloaded 1,000 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $46.94, for a total value of $46,940.00. Following the sale, the director now directly owns 15,625 shares of the company’s stock, valued at approximately $733,438. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Lannett Company (NYSE:LCI) traded up 0.15% on Wednesday, hitting $47.27. 473,784 shares of the company’s stock traded hands. Lannett Company has a 1-year low of $10.18 and a 1-year high of $48.613. The stock has a 50-day moving average of $40.05 and a 200-day moving average of $37.24. The company has a market cap of $1.681 billion and a P/E ratio of 42.45.

Lannett Company (NYSE:LCI) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.03. The company had revenue of $80.00 million for the quarter, compared to the consensus estimate of $84.50 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s revenue for the quarter was up 105.0% on a year-over-year basis. On average, analysts predict that Lannett Company will post $1.75 earnings per share for the current fiscal year.

LCI has been the subject of a number of recent research reports. Analysts at Canaccord Genuity initiated coverage on shares of Lannett Company in a research note on Tuesday, May 6th. They set a “buy” rating and a $55.00 price target on the stock. Analysts at Zacks downgraded shares of Lannett Company from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 9th. They now have a $37.80 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Lannett Company has an average rating of “Buy” and a consensus price target of $42.95.

Lannett Company, Inc is engaged in developing, manufacturing, marketing and distributing generic versions of branded pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.